文献速递膀胱癌与上尿路尿路上皮癌

BCG联合丝裂霉素对比单用BCG治疗初治非肌层浸润性膀胱癌的随机III期试验

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
PubMed 文献 · Eur Urol · 2026-02-02

ANZUP 1301研究纳入501例BCG初治NMIBC患者,随机1:1接受BCG+丝裂霉素或单用BCG,中位随访48个月,两组无病生存无显著差异(2年DFS率75% vs 71%,HR 0.87,95%CI 0.65-1.16,p=0.3)。联合组BCG剂量减少39%、治疗中断更少,提示其可作为单用BCG的务实替代方案以缓解BCG短缺。

要点

  • BCG+MM较单用BCG未显著改善无病生存(HR 0.87,p=0.3)
  • 联合组BCG总剂量减少39%(2056 vs 3383剂),中位9 vs 16剂
  • 联合组完成≥75%计划剂量的比例更高(78% vs 68%,p=0.02)

核心结论

  • 在BCG初治NMIBC中,BCG+MM未证实优于单用BCG,但所需BCG剂量减少39%且治疗中断更少,可考虑作为务实替代以缓解BCG全球短缺。

研究设计与样本

  • 随机1:1对照III期试验(ANZUP 1301),纳入BCG初治NMIBC患者(高级别pTa或任何级别pT1,允许合并CIS),最大程度经尿道切除后分组。
  • 共随机501例:BCG+MM组249例,单用BCG组252例;pTa占53%,pT1占47%,合并CIS占28%;中位随访48个月。
  • 主要终点为无病生存(DFS),次要终点包括3个月膀胱镜完全缓解(CR3mos)、复发、进展、不良事件(AE)及全因死亡。

主要发现

  • BCG+MM较单用BCG的DFS无优势:2年DFS率75% vs 71%,HR 0.87(95%CI 0.65-1.16),p=0.3。
  • 事件数BCG+MM vs 单用BCG:CR3mos为214 vs 210,复发79 vs 86,进展28 vs 44,死亡26 vs 23。
  • BCG+MM组灌注次数更多(4033 vs 3383次),但BCG总剂量更少(2056 vs 3383剂;中位9 vs 16剂)。
  • 3-5级AE在BCG+MM组为43例,单用BCG组为37例;完成≥75%计划剂量者分别为78% vs 68%(p=0.02)。

关键数值与推荐

  • DFS:2年DFS率75% vs 71%,HR 0.87(95%CI 0.65-1.16),p=0.3,未达优效。
  • BCG剂量:BCG+MM组总2056剂、中位9剂;单用BCG组总3383剂、中位16剂,联合组减少39%。
  • 计划剂量完成率:≥75%计划剂量者78% vs 68%,p=0.02,联合组更高。
  • 安全性:3-5级AE为43例(BCG+MM)vs 37例(单用BCG)。

临床怎么用

  • 对BCG初治NMIBC,BCG+MM可作为单用BCG的务实替代方案,尤其在BCG供应短缺时减少BCG用量。
  • 联合方案BCG总剂量更少且完成计划剂量比例更高,或有助于降低治疗中断。
  • 联合组3-5级AE例数略多,临床选择时需结合患者耐受性个体化评估。

局限性

  • 原文摘要未报告具体的统计效能、亚组分析及长期随访数据,相关结论需谨慎外推。
  • DFS未达优效仅为统计学结论,联合方案在进展等次要终点上的差异未做显著性检验,不能据此确立临床优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Intravesical bacillus Calmette-Guérin (BCG) plus mitomycin (MM) had not been compared rigorously with BCG alone in BCG-naïve, non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: Participants with BCG-naïve NMIBC (high-grade pTa or any grade pT1; concurrent carcinoma in situ [CIS] allowed) were assigned randomly (1:1) to either the BCG + MM or the BCG-alone group after maximal transurethral resection. The primary endpoint was disease-free survival (DFS); the secondary endpoints included a complete response on cystoscopy at 3 mo (CR3mos), recurrence, progression, adverse events (AEs), and deaths from any cause. KEY FINDINGS AND LIMITATIONS: We randomised 501 participants (249 to BCG + MM and 252 to BCG alone), with pTa in 53%, pT1 in 47%, and concurrent CIS in 28%. The median follow-up was 48 mo. DFS was not superior for BCG + MM versus BCG alone (2-yr DFS rate: 75% vs 71%; hazard ratio 0.87, 95% confidence interval 0.65-1.16; p = 0.3). The numbers of events for BCG + MM versus BCG alone were as follows: 214 versus 210 (CR3mos), 79 versus 86 (recurrence), 28 versus 44 (progression), and 26 versus 23 (death). Those assigned BCG + MM had more instillations (4033 vs 3383) but fewer doses of BCG (total 2056 vs 3383; median nine vs 16) than BCG alone. Grade 3-5 AEs occurred in 43 assigned BCG + MM versus 37 assigned BCG alone. A higher number of participants assigned BCG + MM than those assigned BCG alone had ≥75% of their planned doses (78% vs 68%, p = 0.02). CONCLUSIONS AND CLINICAL IMPLICATIONS: BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations. These findings support consideration of BCG + MM as a pragmatic alternative to BCG alone, which could mitigate the global shortage of BCG.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. 2026. PMID: 41633899. doi:10.1016/j.eururo.2026.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。